治疗前血清碳酸氢盐预测局限性非小细胞肺癌立体定向放疗后原发肿瘤控制
本研究探讨治疗前血清碳酸氢盐水平与局限性非小细胞肺癌患者接受立体定向体部放疗(SBRT)后原发肿瘤复发的关系。训练队列110例患者114个肿瘤,验证队列195例患者208个肿瘤,两个队列均显示碳酸氢盐<26 mEq/L与原发肿瘤复发独立相关。治疗前碳酸氢盐可能有助于风险分层,但需前瞻性研究证实。
要点
- 治疗前血清碳酸氢盐<26 mEq/L与非小细胞肺癌SBRT后原发肿瘤复发独立相关。
- 训练队列多因素分析HR=5.48(95%CI 1.37-25.19,p=0.020)。
- 验证队列多因素分析HR=3.33(95%CI 1.18-10.07,p=0.023)。
核心结论
- 治疗前血清碳酸氢盐可预测局限性非小细胞肺癌SBRT后的原发肿瘤控制,可能有助于风险分层。
- 该发现需前瞻性研究进一步证实。
研究设计与样本
- 训练队列纳入110例患者共114个肿瘤,中位随访15.0个月。
- 验证队列来自三家合作机构,纳入195例患者共208个肿瘤,中位随访27.5个月。
- 纳入标准为局限性非小细胞肺癌、接受生物有效剂量(BED)≥100 Gy的SBRT、治疗前3个月内有碳酸氢盐检测值。
- 采用受试者工作特征分析确定预测原发肿瘤复发的最佳碳酸氢盐浓度。
主要发现
- 训练队列中碳酸氢盐<26 mEq/L与原发肿瘤复发在单因素分析中相关(HR=5.92;95%CI 1.69-24.88;p=0.005)。
- 训练队列多因素分析显示碳酸氢盐<26 mEq/L与原发肿瘤复发独立相关(HR=5.48;95%CI 1.37-25.19;p=0.020)。
- 验证队列中碳酸氢盐<26 mEq/L与原发肿瘤复发在单因素分析中相关(HR=3.38;95%CI 1.27-9.37;p=0.015)。
- 验证队列多因素分析显示碳酸氢盐<26 mEq/L与原发肿瘤复发独立相关(HR=3.33;95%CI 1.18-10.07;p=0.023)。
关键数值与推荐
- 碳酸氢盐阈值<26 mEq/L用于预测原发肿瘤复发。
- SBRT生物有效剂量(BED)要求≥100 Gy。
- 治疗前碳酸氢盐检测需在治疗前3个月内完成。
临床怎么用
- 对拟接受SBRT的局限性非小细胞肺癌患者,可关注治疗前血清碳酸氢盐水平以辅助风险分层。
- 碳酸氢盐<26 mEq/L提示原发肿瘤复发风险较高,可考虑加强随访或个体化治疗策略。
局限性
- 研究为回顾性设计,结论需前瞻性研究证实。
- 训练队列中位随访仅15.0个月,可能不足以充分评估长期复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor aggressiveness and hypoxia are linked to acidosis in the tumor microenvironment (TME). We hypothesized that low pre-treatment serum bicarbonate, potentially correlating with an acidic and hypoxic TME, predicts for poor outcomes after stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). METHODS: We included patients with localized NSCLC treated to a biologically effective dose (BED) ≥ 100 Gy, with available pre-treatment bicarbonate values within 3 months of treatment. We used receiver operating characteristic analysis to determine the bicarbonate concentration optimally predicting for primary tumor recurrence, and evaluated its association with recurrence and survival. We validated our findings in an independent cohort of patients from three collaborating institutions. RESULTS: A total of 110 patients and 114 tumors were included in the training cohort, with median follow-up of 15.0 months. Bicarbonate < 26 mEq/L was associated with primary tumor recurrence on univariate (HR = 5.92; 95% CI 1.69-24.88; p = 0.005) and multivariate analysis (HR = 5.48; 95% CI 1.37-25.19; p = 0.020). The validation cohort consisted of 195 patients and 208 tumors with median follow-up of 27.5 months. In the validation cohort, bicarbonate < 26 mEq/L was again associated with primary tumor recurrence on univariate (HR = 3.38; 95% CI 1.27-9.37; p = 0.015) and multivariate analysis (HR = 3.33; 1.18-10.07; p = 0.023). CONCLUSIONS: Pre-treatment bicarbonate predicts for primary tumor control in NSCLC treated with SBRT and may be useful for risk stratification. These findings should be confirmed prospectively.
引用
- Sebastian N, Wu T, Driscoll E, et al. Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer. Radiother Oncol. 2019. PMID: 31176206. doi:10.1016/j.radonc.2019.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。